Last reviewed · How we verify
BACILLUS ANTHRACIS PROTECTIVE ANTIGEN, ADSORBED
Bacillus Anthracis Protective Antigen, Adsorbed is a marketed vaccine with a key composition patent expiring in 2028. The vaccine holds a unique position in the market due to its specific mechanism of action against anthrax, providing a critical defense against bioterrorism threats. The primary risk is the potential for increased competition post-patent expiry in 2028.
At a glance
| Generic name | BACILLUS ANTHRACIS PROTECTIVE ANTIGEN, ADSORBED |
|---|---|
| Phase | FDA-approved |
| First approval | 2023 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BACILLUS ANTHRACIS PROTECTIVE ANTIGEN, ADSORBED CI brief — competitive landscape report
- BACILLUS ANTHRACIS PROTECTIVE ANTIGEN, ADSORBED updates RSS · CI watch RSS